What is Bloom Burton’s Estimate for TSE:MBX FY2026 Earnings?

Microbix Biosystems Inc. (TSE:MBX) – Investment analysts at Bloom Burton reduced their FY2026 earnings per share (EPS) estimates for shares of Microbix Biosystems in a report released on Wednesday, April 9th. Bloom Burton analyst D. Martin now forecasts that the company will post earnings of $0.02 per share for the year, down from their prior forecast of $0.04. The consensus estimate for Microbix Biosystems’ current full-year earnings is $0.02 per share. Bloom Burton also issued estimates for Microbix Biosystems’ FY2027 earnings at $0.05 EPS.

Microbix Biosystems Price Performance

Shares of MBX opened at C$0.35 on Friday. The company has a debt-to-equity ratio of 22.61, a quick ratio of 5.57 and a current ratio of 7.15. The company has a 50 day moving average price of C$0.43 and a 200-day moving average price of C$0.39. Microbix Biosystems has a fifty-two week low of C$0.29 and a fifty-two week high of C$0.55. The stock has a market capitalization of C$46.10 million, a PE ratio of 13.33 and a beta of 0.34.

Insider Activity

In other Microbix Biosystems news, Director Cameron Lionel Groome sold 200,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of C$0.43, for a total transaction of C$86,500.00. Also, Senior Officer Mark Adrian Luscher sold 70,750 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of C$0.43, for a total transaction of C$30,295.15. In the last ninety days, insiders have sold 476,750 shares of company stock worth $213,995. Corporate insiders own 14.00% of the company’s stock.

About Microbix Biosystems

Microbix Biosystems Inc, a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products.